With an ageing population leading to an increase in diabetes and associated cutaneous wounds, there is pressing clinical need improve wound healing therapies.
Scope and Significance
Cutaneous wound healing is a major burden for healthcare systems worldwide. Here, we review the key tissue engineering strategies in cutaneous wound healing, including scaffolds, growth factors and cellular therapies to create biological skin equivalents. We also address the current challenges and future implications to the ever-evolving scientific research and technology.
Translational Relevance
Normal wound healing is commonly described as four, overlapping and co-ordinated stages:
Haemostasis, inflammation, proliferation and remodelling. The role of endogenous stem cells is crucial to the process. Tissue engineered solutions that combine stem cells, growth factors and a supporting matrix are being used to create products for clinical wound care applications. There has been a recent research focus on systems of stem cell delivery to wound sites, which ensure cell viability and efficacy in promoting wound healing and the regeneration of its appendages.
Clinical Relevance
Management of wounds is a routine part of medical practice worldwide and delays in healing represent a significant clinical and economic burden. From national data in the United Kingdom, the National Health Service manages 2.2 million patients, costing an estimated £5.3 billion. These numbers are ever increasing, especially with an aging population 1 . They also have a higher mortality, prolonged hospital stays, poorer quality of life and increased rate of being in a long-term care facility when discharged 1-3 .
Background
Skin is the largest organ in the body consisting of the epidermis, dermis, subcutaneous tissue layers as well as skin appendages such as hairs and glands, which expands from deep in the dermis to the superficial epidermal layers (Figure 1 ). It is very vascular, highly innervated and is functionally responsible for maintenance of homeostasis of the living body by regulation of temperature, hydration, vitamin D synthesis as well as the all-important protective barrier against external chemicals and pathogens. Damage to any part of this organ from the development of a skin wound will inevitably compromise the functional properties mentioned above, exposing individuals to the risk of other health complications.
Normal wound healing is commonly described as four, overlapping and precisely co-ordinated stages:
Haemostasis, inflammation, proliferation and remodelling 4 . During the first stage, when the epidermal barrier is violated, keratinocytes react to cell damage. Haemostasis is achieved by endothelial activated vasoconstriction and the clotting cascade. Platelets degranulate alpha granules, leading to secretion of growth factors and pro-inflammatory cytokines 5 . The inflammation phase also begins early with one of the predominant cell types at this stage being neutrophils acting to debride the wound. Another important group of cells are monocytes, which, regulated by TGF-β, transform into macrophages. These further amplify the inflammatory response and the formation of granulation tissue as the proliferative phase is entered, lasting up to 14 days 6, 7 . This phase encompasses the multiple processes of angiogenesis, epithelialisation, granulation tissue and collagen deposition. As part of the formation of granulation tissue and laying down of extracellular matrix (ECM), endothelial cell proliferation and angiogenesis has to occur. This is stimulated by vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) 2, 8 . Fibroblasts are the predominant cell type in the early stages. Some of this population transform into myofibroblasts, which are responsible for wound contraction. Fibroblasts secrete components of ECM which form the foundations for the healing skin 9 .
The re-epithelialisation process with epithelial cell proliferation and migration starts early after injury and continues into the remodelling phase which can last from months to years. The initial increased fibroblast activity results in laying down of type III collagen which initially may account for 30% of the healing wound collagen. Gradually this is replaced by type I collagen and by the second week, type I production is predominant again. Both type I and III are produced during wound healing, but it is the ratio of their production that determines the proportion of collagen type. Net collagen accumulation peaks at around the third week after injury. Throughout the rest of the remodelling stage, collagen is produced at elevated rates without an overall net increase. This is due to collagen production being balanced by degradation 10, 11 .
Chronic wounds have decreased levels of growth factors, display abnormal ECM function and poor blood supply, in addition they show increased levels of the inflammatory interleukins and TNF which which prevents the start of the proliferative stage of healing and can hinder the remodelling process.
An overview of the key contributing cells and factors involved in wound healing are presented in Table 1 .
Wounds in the clinical setting
There have been significant advancements to the manufacturing of wound care products over the last few decades. To be able to maximize healing potential through the choice of management options, it is important to have an understanding of different wound types and the pathophysiology of wound environments. Figure 2 broadly defines the different types of wounds seen in a clinical setting 14 . The most common types of chronic wounds being treated include leg ulcers of vasculopathic and diabetic origin, pressure ulcers and surgical or traumatic wounds 1 . It is well established that some patient characteristics predispose them to delayed wound healing. Local factors include oxygenation, infection, foreign bodies or venous disease. Important systemic factors are age, stress, ischaemic factors, obesity, immunosuppression, smoking and nutrition 15 . Certain co-morbidities have also been shown to be independent risk factors for developing open wounds or ulcers.
We have overviewed wound type by severity, and listed specific challenges each type of wound exhibits and strategies used to overcome these ( Figure 2 There are several approaches to wound management in the clinical setting and to consider each one in detail would go beyond the scope of this review. As this article is most concerned about current tissue engineered strategies for wound healing, the use of skin substitutes will be discussed. Skin substitutes can be used alone or as an adjunct to skin grafting for wound coverage, depending on which layers of the skin the product is designed to support. Horch et al. have described three types of skin substitutes which have been classified according to the relevant biological action in patients 16 . These were historically developed from how surgeons treated wounds in clinical practice and is summarized in Table 2 .
The relevance of this table is seen in how the different commercially available skin products are aimed at different types of wounds treatments ( Figure 2 and Table 3 ). This distinction is particularly helpful for researchers in this field to be able to tailor tissue engineered products to the required patient groups.
The challenge of generating tissue repair is therefore the ability to regenerate native tissue in a manner that allows for the restoration of function to the lost tissue in both acute and chronic wound settings.
Tissue engineering can provide the necessary ingredients to replicate tissue via the use of three central components: scaffolds, cells and growth factors, to develop three-dimensional structural units which aim to restore the function to cutaneous tissue 17 . Strategies mainly involve covering wounds with native matrix and/or polymer scaffold dressings, injection of cells directly to the wound site, or indeed cell encapsulation within materials that can then be implanted.
In the following sections we review the key strategies in the use of tissue engineering in cutaneous wound healing, including scaffolds, cellular therapies and growth factors to create biological skin equivalents. We also aim to address the current challenges and future implications to the everevolving scientific research and technology.
Systematic literature review methodology
In order to summarise the key research avenues currently being explored for addressing cutaneous wound healing we have performed a systemic search of the available literature with particular focus on the use of cells and scaffolds in animal wound healing models. The final search term was chosen based on the raw number of hits and the proportion of experimental verses reviews or opinion papers.
The search term used was (Scaffold OR "Mesenchymal stem cell" OR Biomaterial OR "cell based therapy") AND ("Diabetic wound" OR "skin wound") AND ("ischemia" OR "hypoxia"). The search was performed in Google scholar with restrictions on date from 2006-2016, and on English language papers only. The first exclusion pass was based on the title only. Papers were excluded if they were found to meet any of the following criteria: The initial search returned 3901 papers. After the first pass this was reduced to 238 papers. Following the first pass, remaining papers were reviewed for scientific quality and variables of interest.
A set of variables relating to methodology and results were created, any papers for which two or more of the chosen variables could not be extracted were excluded. After the second pass 121 papers remained for comparative review.
The variables assessed in this review were chosen with an initial aim to perform a meta-analysis of the effectiveness of various scaffold/cell therapy based treatments and highlight promising research avenues. Despite many high quality individual papers reporting significant results on the basis of well constructed experimental procedures, the heterogeneity in approaches and protocols prevents metaanalysis of the data.
Despite being unable to perform meta-analysis of wound healing efficacy many of the individual works still report findings of crucial importance to the progression of the wound healing field. Some of these are highlighted in the relevant sections of this review.
Discussion

Experimental approaches
The heterogeneity and lack of standardised protocol/approach to reporting of results frustrated any meta-analysis of the systematic review data. This problem is well-recognised and reported in other literature surveys involving in vivo animal studies [18] [19] [20] . One such instance found was the lack of standardized method or calculation for measuring the size of the wound and reporting the rate of healing. Another discrepancy of approach was the use of splints to prevent wound closure by contraction. This is of particular importance in rodent studies in which wound healing occurs predominantly via contraction rather than epithelial migration as it does in human wound healing 21 .
Great heterogeneity can also be found in the type of animal model used and in use of diabetic or immunocompromised strains. Faster research progress in the field could be achieved by a more standardised approach to animal model use, which would allow for large meta-analyses. We report data gathered from the literature review to allow future researchers to standardise their methodology against the consensus in the field where appropriate. Data are shown in Figure 3 for: the proportions different animal models; the use of splints with and without immunocompromised animals; the initial wound sizes created and length of study. that had migrated to the epidermis after damage 24 . Since this work many other researchers have used a wider variety of markers to demonstrate the presence of these cells in the epidermis long after wound healing 25 . However, recent controversy has emerged over the time course of the hair follicle bulge stem cells' involvement in wound healing. Whilst Langton et al. have shown that in the absence of these stem cells, the initial wound healing rate (4 days) is significantly reduced 26 ; more recently Garcin et al. showed that these cells may in fact be excluded from the early stages of wound healing for excisional wounds 23 .. In the case of burns, the hair bulge's regenerative function has been particularly noted: Superficial burns, which leave the structures intact (see Figure 2 ) heal rapidly and regenerate epidermal appendages. With more severe burns in which the hair bulge is affected, the regenerated skin shows scarring and lacks adnexal structures 27 .
Role of cells in wound healing
The use of cultured epithelial autografts (CEA) for treatment of burns has been used to treat cutaneous defects since it was described by Green et al. in 1979 28 . This was based on the hypothesis that delivery of the CEA would deliver the inherent skin stem cell population and would enhance wound healing. However, researchers were quick to realise that applying CEA alone into wounds did not achieve good clinical results 29 . Clinically, they were cumbersome to use and patients experienced poor quality of healing with frequent blistering and wound contractures months after grafting 30, 31 .
Since then, studies have shown that providing matrix support and a delivery system for CEA improves its in vivo success, leading to the development of bio-engineered cultured skin substitutes 32, 33 . There is still a role for cellular therapies, such as the commercially available Epicel ® (Genzyme), through the instant replacement of lost cell mass in difficult-to-treat wounds, although its efficacy and economical benefits compared to other advanced therapies has yet to be determined 34 .
From our analysis of the literature, cellular therapies utilised a variety of cell sources. The predominant cell were stem cells (81.9%) which included bone marrow, adipose derived stem cells, as well as umbilical cord, and Wharton's jelly MSCs. Fibroblasts were the next most common cell type (7.1%). Table 4 lists all cell sources found in the reviewed literature. In order to understand the progression of various cellular therapies currently used for wound healing, the difference between stem cell versus differentiated cells needs to be first appreciated. Differentiated cells, such as fibroblast and keratinocytes, form the basis of commercially available autologous and allogeneic cellbased products. Some products have been on the market since the late 1990s. Their role in skin substitute products, such as Dermagraft ® (Organogenesis Inc.) and Apligraf ® (Organogenesis Inc and Novartis), is to provide the necessary materials for wound closure via the laying down of matrix proteins and production of growth factors 35, 36 . This stimulates healing by promoting host cell migration and infiltration, as well as neoangiogenesis into the wound bed, thereby enhancing rapid reepithelialisation and closure of the wound. However, there are inherent disadvantages with using allogeneic products. All though the risk is very low, there is a possibility of disease transmission and graft rejection 37 . Conversely, it has been shown in several studies that allogeneic differentiated cells delivered via the biological skin substitute Alipgraf ® do not persist in the wound site beyond six weeks, which may explain why rejection is not commonly reported in literature 38, 39 . Despite such theoretical benefits, researchers and clinicians still experience limited success with its use. Reported clinical trial studies, using differentiated cell-based products, have shown a collective success rate in wound closure of 35%-56%, leaving approximately half of the wounds ineffectively treated and vulnerable to the risk of infection and other complications 40 . This has prompted researchers to consider stem cells based therapies as a possible solution to further improve wound healing.
Stems cells' capacity for self-renewal and their inherent clonogenicity and potency make them fundamental in the healing and regeneration of bodily tissues. From the wound healing perspective, stems cells have the potential of correcting the biological deficiencies in chronic wounds, thereby offering the potential of complete skin regeneration, including the restoration of the skin appendages.
Although embryonic and induced pluripotent stem cells have the most valuable potency of all cells to differentiate and regenerate, the ongoing issues around the ethics and safety of its use have prompted researchers to focus more on the other stem cell populations such as mesenchymal stem cells (MSCs) instead.
The delivery of MSCs to wounds is gaining popularity in this field. There are distinct advantages of the use of MSCs over differentiated cells. They are known to possess beneficial immunomodulatory effects, such as immune suppressive and immune privilege functions, theoretically making its allographic uses more suitable from that respect 107 . They also have a strong trophic capability of releasing the necessary pro-regenerative cytokines and growth factors for regeneration 108, 109 and their ability to differentiate provides a potential cell source for native tissue restoration (See Figure 4 ). All these help to provide further building blocks to the healing process 110 . Conversely, there is also a growing body of evidence showing that the therapeutic effect of implanted MSCs comes from the release of necessary secretomes rather than long-term contribution to the structure and transdifferentiation [114] [115] [116] . What is clear, however, is the fact that MSCs have the right regenerative characteristics and potential to improve wound healing where differentiated cells are not implanted. A direct comparison of the role of stem cells to commercially available differentiated cells would be helpful to both researchers and clinicians, but studies in this field are currently lacking.
Interestingly, stem cells have been shown to display cellular cross-talk with differentiated cells when co-cultured together, improving and enhancing the therapeutic potential in wound healing. Aoki et al.
demonstrated how bone-marrow derived MSCs interacts with keratinocytes such that rete ridge-like structures were created in regenerated epidermis in its presence indicating the benefits of cellular diversity within the wound healing environment 117 . However, there exist conflicting evidence on the importance of these cellular interactions as shown in a study by Rodriguez-Menocal et al. 118 . 'Dosedependent' effects were reported in their in vitro study, where it was shown that higher levels of cocultured MSCs inhibited fibroblast migration whereas lower doses of MSCs actually enhanced fibroblast migration patterns. Therefore better understanding of co-culture cellular dynamics , especially with the use of stem cells is needed, and further research will be needed to address this void.
Delivery systems
There are 4 main mechanisms through which cells are delivered to wounds in vivo. These include delivery through topical spray, direct injection, systemic delivery and cell-seeded scaffolds.
Each delivery mode has advantages. The topical spray and direct injection are easy to administer but difficult to localise cells long term as cells can 'escape' the delivery site. As cells are not encapsulated within a material or matrix, these cells are also considered non-protective 110 . With a systemic delivery of cells, there is reason to believe that stem cells in particular may 'home-in' on the wound site, however this is not certain and the localisation of other cells at the wound is unlikely. Generally, it is accepted that 3D scaffolds (either native matrix rich or polymer), afford cells within them a protective environment and enable one to localise cells to a wound site 110 . Modification of scaffolds' material properties, including degradation times, stiffness, porosity and incorporation of growth factors and/or drugs, is also possible.
There is an emerging appreciation of supporting the stem cell niche in its 3D state, as it is known that maintenance of stem cell pluripotency or multipotency and differentiation is associated with specific micro-environmental cues. These niches provide a set of unique and specific features that help to maintain multipotency proliferation and differentiation an regulate stem cell maintenance .
The specific microenvironmental features include chemical signals (including growth factors), cellcell adhesion and interactions, cell-matrix attachment, mechanical features, stiffness and oxygen environment 119, 120 . There is thus, a need to understand which features can influence specific stem cell behaviours we may wish to manipulate, in this case related to the wound healing process. The systematic review data reflects the growing awareness of the importance of the biomimetic niche over the past 10 years. Figure 5 shows the relative proportions of studies which utilize scaffolds, cells and growth factors and the combination thereof.
The importance of scaffolds in wound healing
As discussed above, cells in vivo reside within distinct microenvironments which help to direct cell function, state and signalling. Such microenvironments are critical to wound healing, therefore it is crucial that any cell based therapies, support new or host cell populations by providing a suitable microenvironment. Only in such cases will cells contribute maximally to tissue regeneration and repair. Culturing cells within a 3D environment such as a scaffold, is a method that aids in the creation and maintenance of specific microenvironments or biomimetic niches.. In the case of delivering cell-seeded scaffolds into wound defects, this can allow for new tissue genesis 110 . This greater appreciation of the native 3D microenvironment has brought about the emergence of biomimetic scaffolds that aim to create a biomimetic cell niche, with particular attention to the stem cell niche. Biomimetic tissue engineered scaffolds make use of biomaterials that mimic one or multiple characteristics of the native ECM 121 . This can be in the form of its biodegradability, mechanical properties, matrix composition and/or architecture. There are two main types of tissueengineered scaffolds, biological and synthetic.
Biological scaffolds can exist as organic molecular polymer or as matrix protein, such as collagen and hyaluronic acid. These scaffolds tend to contain a maximum of 3 matrix components, so are relatively simple in terms of composition. There is also the use of decellularized (acellular) allogeneic or xenographic derived dermal matrices (ADM), which are complex in terms of matrix composition and architecture. Using an ADM as a biological modulator is specifically thought to interrupt the continuous inflammatory process characteristic of chronic wounds and in so doing lead to angiogenesis, cell infiltration and re-epithelialization 122 . However, only small numbers of good quality clinical trials exist for supporting usage of ADM's in chronic wounds and the exact mechanism of action is not fully understood [122] [123] [124] . The main processes used to decellularise tissues include detergents, hypo-and -hypertonic solutions, enzymes and chelating agents 124 . The process by which tissues are decellularized is critical as it determines (i) retention of matrix proteins, (ii) maintenance of matrix architecture and (iii) retention of growth factors sequestered within the matrix. Overall, it seems that decellularized acellular dermis potentially provides the most biomimetic matrix to host the all-important cellular niche for tissue engineering purposes.
Commercial wound dressings products commonly use molecular polymers and matrix proteins.
Research on tissue engineered wound healing products have mostly moved away from the use of single biomolecular agents on wounds, favouring more sophisticated biologically processed acellular matrix to provide the necessary ECM template for wound healing (Table 1) . They can now be found in combination with other biomaterials, such as Apligraf ® (Organogenesis Inc.), or as carriers for delivery of cellular products, such as Laserskin ® /Vivoderm ® (Fidia Advanced Biopolymers/ER Squibb & Sons Inc), to create more complex tissue engineered products for wound healing.
An advantage of synthetic scaffolds, is that they can be customised for purpose in a controlled environment to mimic the tissue architecture of interest. Another major advantage with synthetic scaffolds is the possibility of mass-production,, facilitating the key goal of providing a point-of-care product in tissue engineered wound care. First described by Yannas and Burke in 1980, the design and use of artificial skin has been an evolving science 125 .
Currently opinions in such research are turning towards the use of both organic and inorganic composite materials combined together to create a hybrid scaffold for skin tissue engineering 126 .
Organic scaffold components address the need for a biological proteins to provide a favourable environment for cells to proliferate and differentiate; whist inorganic components may facilitate manufacture process and quality control.
It is important to emphasise that scaffolds used alone without the addition of any other cellular or bioactive molecules only promote healing via secondary intention. Therefore, the scaffold influence is to mainly assist the in vivo host response in wound repair by provision of the right environment for cell and tissue adherence. Hence, these products are typically used in combination with the conventional gold-standard split thickness skin grafts.
In addition, there is increasing use of scaffold-based delivery systems for stem cell transplantation over other delivery modalities. The driving hypothesis here is that the 3D environment provides cells with the necessary protection and matrix spatial cues for the seeded cells during the delivery process 110 . There are also key advantages in the use of cell-seeded scaffolds over cell-only therapies in wound healing, especially for larger wounds. 3D scaffolds provide greater coverage as well as help to maintain integrity of tissue architecture during wound healing.
Scaffolds may be engineered in a variety of ways. Despite decellularized skin being the most biomimetic of biological scaffolds, limited availability of donor skin and shelf life of such products would deny it from being a solution to the growing demand for tissue engineered skin products. More recently, researchers have been turning to the use of 3D bioprinting technologies as another viable option for skin replacement [127] [128] [129] [130] [131] . Bioprinting allows for precise and predefined positioning of living cells and other biological material, enabling the manufacture of customizable tissue constructs based on computer generated designs 132 . Bioprinting is a layer-by-layer process, hence it allows for the creation of smaller functional tissue units made up of cells which can subsequently be assembled together like building blocks into larger, more complex organs 132 . The skin as an organ, having a layered structure, is highly suited to this printing technology. Mini-tissue blocks with functional units, such as adenexal structures, can technically be recreated using 3D bioprinting using the relevant skin cells types 133 . Amongst all the successful in vivo models, Cubo et al. have successfully bioprinted and transplanted human skin made up of cells from skin biopsy and have shown the resultant regenerated skin to be histologically similar to that of normal human skin 130 . Hence it is no surprise that the feasibility of this technology has caught the attention of the commercial industry, with bioprinting company Organovo collaborating with cosmetic giant L'Oreal US to invest and research into the bioprinting of skin in 2015 134 . Despite its great potential, this field is still very much in its infancy and will require a few more years of fine tuning of it technology before it finds it way to the bedside 132 .
For all scaffolds, the manufactory process must take into account the specific tissue microenvironment that the scaffold aims to mimic. Mechanical, physical and biochemical modifications, are often introduced applied to scaffolds to enhance their wound healing potential 16 .. Figure 6 depicts seven features of the cellular microenvironment that should be considered when targeting a biomimetic cell niche 135 .
Material properties: Recent studies have shown that strength and type of intermolecular bonds
within scaffolds may affect cell proliferation and differentiation 136 . Work has also been done to show that the stiffness of the matrix in which cells are seeded can direct lineage specification 137 . Where these cells are seeded in a 'soft matrix' (Ebrain~0.1-1 kPa) they commit to a neurogenic lineage, compared to being seeded on a stiffer matrix (Emuscle~8-17kPa) where MSCs commit to a myogenic lineage 137 . It is imperative that where stem cells are being delivered to wounds within matrices, this aspect is considered, as MSC fate is influenced by a host of micro-environmental features and triggers.
Matrix composition.
There has been much work done on the importance of integrin-mediated adhesion for stem cell maintenance. Although functional roles for β1 integrin is not completely understood in terms of stem cell maintenance, it is expressed across human MSCs of three different tissue origins including bone marrow 138 . α6 β1 is an integrin associated with attachment to laminin and addition of laminin to scaffolds can enhance the ability of endothelial cells to fuse to form tubelike structures 139 . Collagen/laminin scaffolds were used to deliver MSCs to an in vivo diabetic wound model, with significantly enhanced wound healing compared to collagen I only 140 . This suggests that variation in MSCs' surface integrin expression and the ability to change integrin expression in 3D matrices can direct their behavior. More so, this highlights the importance of an appropriate choice of ECMs for a given cellular population 138 . Within the literature reviewed here a wide variety of scaffold materials were found with 47.9% of studies used a natural scaffold material, 9.2% a synthetic and 11.6% a hybrid of synthetic and natural materials. The three most widely used materials were Collagen or Collagen:Chitosan, Fibrin, and Alginate.
Topographic cues.
There is an increasing body of work which shows that the topographic pattern onto which cells are seeded in vitro, can direct stem cell behavior, including differentiation and commitment to different lineages 141 . It has been found that cells attach to different nanotopographical features on material surfaces with specific integrin receptors and focal adhesions which can contribute to cell fate through changes in both cell morphology and biochemistry 142 .
6.3.4
Hypoxia. Cells cultured in vitro are, in the main, exposed to atmospheric O2 which is far higher than physiological hypoxia, which ranges between 1-9%, and in some cases can be as low as 0% 120, 143 . It is known that oxygen tension can directly affect cell proliferation and differentiation, especially for bone marrow derived mesenchymal stem cells 144 . It is also appreciated that a hypoxic environment, even less than 1% oxygen, is critical to maintenance of stem cell pluripotency and quiescence 145 .
Growth factors.
Scaffolds have also been shown to be good vectors for delivery of growth factors and other necessary biomolecules beneficial to wound healing such as anti-inflammatory and antioxidant substances. Growth factors are indicated in all tissue healing cascades. They are key in coordinating the biological signalling component for cell function and tissue regeneration. They represent biological material that can potentially be used to target distinct wound-healing phases. A variety of growth factors which attempt to target one or several of these phases have been investigated as found through the literature review conducted here and summarised in Table 5 . VEGF, SDF-1-α and FGF are the three most widely used factors. However, given the complexity of the wound healing process, the exogenous use of growth factors does not usually produce results of satisfactory wound healing due to difficulties with mimicking the specific endogenous growth factor production. One effort to replicate this complexity is to control the release of the growth factor to create a more biomimetic environment and a longer lasting therapeutic effect 135, 178 .
There are two primary ways in which the release from scaffolds can be modulated, either by altering the porosity or surface area of the scaffold to control the rate of diffusion of the factors through and out of the scaffold or via chemical binding of the factor to the scaffold. In the former case the rate of release of the factor depends on a factors diffusivity through the scaffold, the relative concentration of the factor within the native tissue, and the rate of uptake or utilisation of the factor by cells.
Control of the scaffold porosity, is often done by altering the concentration of the scaffold's fibrous components. This effect is consistent across many types of scaffold and growth factor, for example for release of SDF-1 from a Poly (polyethylene glycol citrate-co-N-isopropylacrylamide) (PPCN) scaffold 147 , increasing the concentration of the polymer slows the release of SDF-1-α into the surrounding media. Similarly increasing the chitosan proportion in a collagen:chitosan sponge, produces slower release of Thymosin-β-4 172 . In addition to controlling the initial scaffold density controlling the scaffolds surface area will affect not only the diffusion of the factors through the scaffold surface, but has also been shown to affect the scaffold degradation rate. As the scaffold degrades, factors will be released at a greater rate. By controlling the degradation rate, the release of the scaffold may also be controlled. Fibrin microspheres within a fibrin scaffold described by Kulkarni et a 179 , show some spatio-temporal control over the release of two factors through exploiting the differing degradation rates of microspheres as compared to larger fibrin gels. Although such approaches represent an highly interesting avenue of research, the temporal control over the release of such factors with these methods is highly simplified by comparison to those released via cellular mechanisms.
The alternative method to controlling factor release is to bind the growth factor chemically or electrostatically to the scaffold. Two such systems were found in the literature reviewed. Fibrin binding bFGF was shown to increase angiogenesis of implanted scaffolds 156 , as was fibrin binding VEGF 151 . Another approach is to bind cells into the scaffolds through similar techniques, Wang et al. 174 utilised a collagen scaffold with a collagen binding peptide with an affinity for MSCs. Using a porcine model the authors report an increase in wound closure rate for the binding scaffold as compared to a non-binding scaffold as well as increased cell retention 174 .
6.3.6
Architecture. Tissue architecture dictates physical properties of tissues. For example, the orthogonal pattern of collagen fibrils in cornea confer transparency to that tissue, whilst the parallel array of a bi-modally distributed collagen diameter size confers mechanical strength to tendon in one plane 180 . Skin is a meshwork of interwoven ECM proteins which give skin anisotropic properties, which helps to give skin its flexibility. In regeneration of skin, scarring can limit the flexibility of new skin and therefore strategies to reproduce the normal architectural woven structure of skin are desirable. This biomimetic feature may be introduced into a scar by grafting de-cellularized skin, with the hope that cells would use the biomimetic cues to align themselves and deposit matrix using the scaffold cues 181 . There is also an emerging view that whereas tissue architecture is seen as a consequence of cell behaviour, mainly deposition of matrix protein and application of strain and tension applied to tissues, it is likely that tissue architecture itself may direct cell behaviour and fate 182 . So cells within an aligned tissue are likely to stress shield and align along principal axis of strain. They are also more likely to deposit matrix along this alignment.
The interactions of cells with the native scaffold within tissues can direct and influence cell behaviour. It is critical to decipher the specific components of microenvironment which can successfully deliver cells to an injury site and direct them to aid tissue repair and re-growth.
Future of tissue engineering in wound repair
The end-goal for tissue engineering in wound repair is to be able to provide patients with high quality, universal 'off the shelf' skin substitutes which can regenerate skin in wounds as quickly as possible, with minimum scarring. There are still significant challenges in this rapidly evolving research field to be able to achieve this goal. Skin substitute products currently available to patients can only go so far as to partially replace the skin as a protective barrier. However, functional restoration such as its innervation, thermoregulation, perspiration, melanin production as well as aesthetic appearances have yet to be achieved by current bioengineering techniques. It seems the next steps for tissue engineered skin products is the marriage between the use of stem cells within a tissue engineered scaffold to be able to achieve such a full regeneration of skin. Although there are several pre-clinical animal research incorporating such techniques, there only been a handful of clinical studies looking at the usage of MSCs in combination with a biological scaffold to aid skin wound healing in humans. This is summarized in Table 6 .
A 2005 study in Japan experimented in a murine model with a bovine-derived collagen sponge (Terudermis) impregnated with a suspension of cells derived from bone marrow 183 . They showed that the rate of angiogenesis in a healing wound was greater in the mice population implanted with collagen matrix containing bone marrow suspension compared with the control group. Their paper also reported a case report of a chronic leg ulcer that was treated with Terudermis impregnated with autologous bone marrow cell suspension. Two weeks following application, healthy granulation tissue had formed and a split thickness skin graft was performed, with successful outcome at long-term follow-up. Although the paper did not specifically mention MSCs, the BM derived cell suspension would have contained some. Yoshikawa et al. in 2008 reported the use of artificial dermis (Pelnac) soaked with marrow mesenchymal stem cell suspension on 20 subjects with chronic lower limb wounds 184 . In nine cases, this composite graft was placed on the wound and allowed to heal secondarily. In five cases, the composite graft was followed by a split thickness skin graft. Finally, in six cases, diced full thickness skin graft pieces were placed on the wound before the composite graft was applied. 16 of the 20 cases demonstrated complete healing of the chronic defect. The remaining four partially healed, of which 2 subjects died prior to study conclusion. Most recently, Ravari et al. in 2011 published data on eight patients who had chronic diabetic foot ulcers 185 . The authors used a very different approach to the studies in Japan and utilised an intensive combined technique.
Autologous BM aspirate were injected into a debrided wound bed. A mixture of more suspension, platelet growth factors and fibrin glue was then applied and allowed to form a clot. Finally, BM aspirate impregnated collagen matrix (Surgicoll) was placed on top. Three patients had complete wound closure and the others significantly decreased in size (average wound area decrease was 57%, range 24-79%). Again, the paper did not specifically mention mesenchymal stem cells in the aspirate, but some would have been in the suspension. Table 6 summarises the key features of each study. There is a paucity of cutaneous wound healing clinical studies that utilize both BMMSC's and dermal matrices. Preliminary data are from case reports and series, but nonetheless seem to reveal real clinical potential. Further evidence from good quality, well-powered, double-blinded RCT's are needed before its place can be established in the armament of options for chronic wound healing and reconstruction.
However, it is worth noting that there has been some degree of success of MSCs delivery to patients with wounds resulting from peripheral vascular disease, which have been demonstrated in several published clinical trials. In double blind randomised placebo-controlled trial by Powell et al., they found that intramuscular injection of patient-specific, expanded bone marrow cells (CD90+ MSCs and CD14+ monocyte/macrophage subset of CD45+ hematopoietic cells) may have resulted in the prevention of wound area doubling, delayed time to treatment failure as well as prolonged amputation-free survival in the leg of patients with baseline wound from critical limb ischaemia 186 .
Clinical trials have also shown there is an advantage over using bone marrow derived stem cells compared to bone marrow derived mononuclear cells at significantly enhancing limb perfusion and ulcer healing rates in patients with diabetes and peripheral vascular disease 187 . These studies have found a potential for therapeutic angiogenesis through the use of MSC therapy. Due to the underlying pathology of chronic non-healing wounds, these findings can be easily translatable to the treatment of these wounds and beyond.
Despite such clinical possibilities of therapeutic success, there are still important questions which need addressing with regards to the use of stem cell-based therapies, such as which type of stem cell population would be best served for wound healing therapies and what are the safety issues that could potentially arise from the autologous compared to allogeneic stem cell use in a clinical setting. There are very few studies addressing these specific issues, thus making it difficult for researchers and clinicians to have absolute confidence in its future clinical applications 40 . It is very likely that potential complications and safety issues will surface in literature with time, an example seen in a paper published in 2004, almost three decades since the introduction of the use of CEA was advocated. It reported the first case of graft site malignancy in a patient who received CEA to his burns injury more thirteen years ago 188 . Five separate localised skin cancer lesions were diagnosed and completely excised in different anatomical distributions of the body previously exposed to CEA, raising the safety concerns of the use of cellular therapies clinically. Although we must take into account that burns injuries itself carries an innate risk of malignant transformations into squamous cell carcinomas, the author also noted the use of mitogenic stimulators and other chemicals during in vitro expansion which may contribute to an increased risk of cancer 188 . Therefore, such issues must be borne in mind when advocating cellular therapies to patients.
Summary
The field of tissue engineering has come through leaps and bounds over the past decade. There are still many challenges and limitations in the translation of cell therapies for wound healing such as safety, cost and efficacy of treatment. The delivery of stem cells in three-dimensional scaffolds to wounds seems to be the most promising approach. It is safe to predict that as our understanding of stem cell biology improves along with technological advancements in bio-scaffold fabrication; the near future will see tissue engineered techniques become a standard practice for wound regeneration.
Take home messages
1. Experimental measurements of animal model in wound healing should be standardized to facilitate study comparisons.
2. It is important to take into account clinically different wound types when designing and applying tissue-engineering strategies to the management of these wounds.
3. The most widely used cell type for wound healing application are bone marrow derived stem cells. Table 3 . Current available commercial tissue engineered therapies for wound healing. Table 4 . Cell types used in the studies systematically reviewed. Table 5 . Summary of all growth factors used in the studies systematically reviewed. Table 6 . Summary of the clinical trial data, that uses MSCs and ECM scaffolds. Percentage of studies applying either: cells directly to the wound, growth factors directly or a scaffold as well as those which combine these approaches, i.e. scaffold with encapsulated cells, scaffolds with encapsulated growth factors, all three combine or cells with additional growth factors.
Figure 6.
Overview of a number of cell-scaffold interactions to re-create elements of the biomimetic niche. Re-capitulating elements of the biomimetic niche helps to direct cell behavior, response and fate 135 .
